Isothiazolones lower plasma levels of lipoprotein(a)
OwnerJohn Michael Domagala, Helen Tsenwhei Lee +4inventors
InventorsJohn Michael Domagala, Helen Tsenwhei Lee, Randy Ranjee Ramharack, Bruce David Roth, Tomi Sawyer, Drago Robert Sliskovic
Life of this patent
Estimating the term…
Abstract
Plasma levels of Lp(a) are lowered by administering an isothiazolone having the general structure ##STR1## where A is a monocyclic or bicyclic ring which may contain up to 3 heteroatoms selected from O, S, and N; R.sup.1 and R.sup.2 are substituent groups such as alkyl, alkoxy, hydroxy, nitro, cyano, amino, and carboxy; and R.sup.5 is alkyl, cycloalkyl, phenyl, and Het.
Claims17
A method for lowering plasma Lp(a) levels in a mammal comprising administering an Lp(a) lowering amount of a compound of Formula I ##STR117## wherein:
- A is a monocyclic ring having 5 or 6 ring atoms, or a bicyclic ring having from 9 to 12 ring atoms, the ring atoms being selected from carbon and optionally up to 3 heteroatoms selected from O, S, and N;
- R.sup.1 and R.sup.2 independently are hydrogen, halo, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, Het(CR.sup.6 R.sup.7).sub.m -, phenyl-(CR.sup.6 R.sup.7).sub.m -, O-C.sub.1 -C.sub.6 alkyl, hydroxy, nitro, cyano, NR.sup.3 R.sup.4, NR.sup.3 COR.sup.4, CO.sub.2 R.sup.3, CONR.sup.3 R.sup.4, S(O).sub.m R.sup.3, SO.sub.3 H, S(O).sub.m NR.sup.3 R.sup.4, COR.sup.3, or taken together are oxo (O.dbd.) or methylene dioxy (-O-CH.sub.2 -O-);
- m is 0, 1, or 2;
- R.sup.3 and R.sup.4 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, Het(CR.sup.6 R.sup.7).sub.m -, or phenyl-(CR.sup.6 R.sup.7).sub.m -;
- R.sup.6 and R.sup.7 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, CO.sub.2 R.sup.3, hydroxy, CONR.sup.3 R.sup.4, or cyano;
- R.sup.5 is hydrogen, C.sub.1 -C.sub.6 alkyl, COC.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl-(CR.sup.6 R.sup.7).sub.m - , Het(CR.sup.6 R.sup.7).sub.m -;
- and
- wherein the foregoing alkyl, cycloalkyl, phenyl, and Het groups may optionally be substituted with from 1 to 3 groups selected from halo, hydroxy, nitro, NR.sup.3 R.sup.4, NR.sup.3 COR.sup.4, CO.sub.2 R.sup.3, CONR.sup.3 R.sup.4, S(O).sub.m R.sup.3, S(O).sub.m NR.sup.3 R.sup.4, and COR.sup.3, where m, R.sup.3, and R.sup.4 are as defined above;
- and the pharmaceutically acceptable salts and solvates thereof.
A method of employing a compound of the formula ##STR119##
A method for treating restenosis comprising administering to an animal in need of such treatment an Lp(a) lowering amount of a compound of Formula I.
A method for preventing stroke comprising administering to a mammal an LID(a) lowering amount of a compound of Formula I.
A method for treating angina comprising administering to an animal in need of such treatment an LID(a) lowering amount of a compound of Formula I.
Dependencies are inferred from the claim text.